Cancer Expert MD

Lymphoma is a cancer of the lymphocytes, the white blood cells that patrol the lymph nodes, spleen and bone marrow. It is one of the most treatable cancers, many forms are curable, and the treatments available in 2026 are more effective and less toxic than ever. This article explains the main types of lymphoma, the newest treatments, and the integrative factors that research shows can influence outcomes.

A Personal Note

Dr. Silver, MD, is himself a lymphoma survivor of about twenty-five years. His lymphoma was in his neck and across his mediastinum, the center of the chest between the lungs, yet he never felt a lymph node in his neck. He simply did not feel well, ordered his own scans, and they found the lymphoma. His story is a reminder that lymphoma does not always announce itself with a lump. Fevers, drenching night sweats, unexplained weight loss, persistent fatigue and itching can all be signs. Read his story.

The Main Types of Lymphoma

Hodgkin lymphoma often affects younger adults and is among the most curable cancers.

Non-Hodgkin lymphoma is a family of more than sixty types. The most common aggressive type is diffuse large B-cell lymphoma, which is often curable. The most common slow-growing type is follicular lymphoma, which may not need treatment for years.

The exact type matters enormously, so an adequate biopsy, ideally removing a whole lymph node, and expert pathology review are the foundation of good care. PET-CT scans show where the lymphoma is and how it responds to treatment.

Hodgkin Lymphoma: The German Advance

The German Hodgkin Study Group has led the world in Hodgkin lymphoma research for decades. In its HD21 trial, 1,500 patients aged 18 to 60 with advanced Hodgkin lymphoma received either the long-standing intensive regimen called eBEACOPP or a newly designed regimen, BrECADD, which adds a targeted antibody-drug conjugate, brentuximab vedotin, and drops some of the most toxic drugs. Treatment length was adjusted to each patient’s PET scan response. BrECADD cured more patients and caused fewer serious treatment-related problems.¹ Long-term results presented in December 2025 confirmed a higher chance of cure with first-line treatment and a lower risk of serious late effects, including infertility and treatment-related leukemia.

In the United States, the S1826 trial showed that adding the immunotherapy drug nivolumab to standard chemotherapy (nivolumab-AVD) improved progression-free survival over a brentuximab-based regimen.² Patients now have two excellent first-line options.

Diffuse Large B-Cell Lymphoma: From Chemotherapy to Immune Therapies

First-line treatment. For two decades the standard was R-CHOP, chemotherapy combined with the antibody rituximab. In the POLARIX trial, replacing one drug with the antibody-drug conjugate polatuzumab vedotin improved progression-free survival, the first improvement in first-line treatment in about twenty years.³

CAR-T cell therapy. CAR-T therapy reprograms a patient’s own T cells to attack lymphoma. In the ZUMA-7 trial, CAR-T therapy given at first relapse improved overall survival compared with standard chemotherapy and stem cell transplant.⁴ China has developed its own CAR-T products for lymphoma as well.

Bispecific antibodies. These “off-the-shelf” immune therapies link the patient’s T cells directly to lymphoma cells. Glofitamab produced complete remissions in about four in ten patients with relapsed disease, including some whose lymphoma had returned after CAR-T.⁵ At the American Society of Hematology meeting in December 2025, the bispecific antibody mosunetuzumab proved effective as first treatment for older patients too frail for chemotherapy, and trials are now testing bispecific antibodies in first-line treatment for everyone.

A Lymphoma Cured by Antibiotics

Some lymphomas are driven by chronic infection. The clearest example is MALT lymphoma of the stomach, which grows in response to the bacterium Helicobacter pylori. In 1993, researchers reported in The Lancet that eliminating the infection with antibiotics made these lymphomas regress, and antibiotic treatment remains the first-line therapy for early-stage disease today.⁶ It is one of the most striking demonstrations that the terrain in which a cancer grows can drive the cancer itself.

Vitamin D and Rituximab: A German Finding

Researchers in the German High-Grade Non-Hodgkin’s Lymphoma Study Group found that patients with diffuse large B-cell lymphoma who were deficient in vitamin D had worse outcomes when treated with rituximab, and that vitamin D deficiency impaired rituximab’s ability to direct immune cells to kill lymphoma cells. When deficient volunteers took vitamin D, that killing ability improved.⁷ Whether correcting vitamin D improves survival is still being tested, but measuring the level before rituximab treatment is a simple step. Our article on why cancer comes back explains how inflammation and immune function shape long-term outcomes.

When Lymphoma Returns

Relapsed lymphoma is often still treatable, and sometimes curable, with CAR-T therapy, bispecific antibodies, stem cell transplant, targeted drugs and clinical trials. Re-biopsy matters, because lymphoma can change type over time. Our guide to what to do when chemotherapy stops working explains the next steps.

How Cancer Expert MD Helps

Cancer Expert MD provides education and consultation for people with every type and stage of cancer, and specializes in Stage IV, metastatic and relapsed cancer. Our book, The New Reality of Cancer, covers testing, conventional and immune therapies, and integrative approaches across all cancers, including lymphoma.

Frequently Asked Questions

Is lymphoma curable?

Many types are. Most patients with Hodgkin lymphoma and many with diffuse large B-cell lymphoma are cured with first-line treatment. Slow-growing types such as follicular lymphoma are often controlled for many years.

Can you have lymphoma without a lump?

Yes. Lymphoma can grow in the chest or abdomen where nodes cannot be felt. Fevers, night sweats, weight loss, fatigue and itching can be the only signs.

What are bispecific antibodies?

Ready-made immune therapies that connect a patient’s T cells directly to lymphoma cells so the T cells can destroy them. They are used in relapsed lymphoma and are being tested as first treatment.

Does vitamin D matter in lymphoma?

German research found that vitamin D deficiency was linked to worse outcomes with rituximab and weakened rituximab’s immune killing of lymphoma cells. Whether supplementation improves survival is still being studied.

---

For more in-depth information on this topic and many others, get our book, The New Reality of Cancer: The Science of Recovery.

More articles on cancer types and all articles.

References

1. Borchmann P, Ferdinandus J, Schneider G, et al. Assessing the efficacy and tolerability of PET-guided BrECADD versus eBEACOPP in advanced-stage, classical Hodgkin lymphoma (HD21): a randomised, multicentre, parallel, open-label, phase 3 trial. The Lancet. 2024;404(10450):341–352.
2. Herrera AF, LeBlanc M, Castellino SM, et al. Nivolumab+AVD in advanced-stage classic Hodgkin’s lymphoma (S1826). New England Journal of Medicine. 2024;391(15):1379–1389.
3. Tilly H, Morschhauser F, Sehn LH, et al. Polatuzumab vedotin in previously untreated diffuse large B-cell lymphoma (POLARIX). New England Journal of Medicine. 2022;386(4):351–363.
4. Westin JR, Oluwole OO, Kersten MJ, et al. Survival with axicabtagene ciloleucel in large B-cell lymphoma (ZUMA-7). New England Journal of Medicine. 2023;389(2):148–157.
5. Dickinson MJ, Carlo-Stella C, Morschhauser F, et al. Glofitamab for relapsed or refractory diffuse large B-cell lymphoma. New England Journal of Medicine. 2022;387(24):2220–2231.
6. Wotherspoon AC, Doglioni C, Diss TC, et al. Regression of primary low-grade B-cell gastric lymphoma of mucosa-associated lymphoid tissue type after eradication of Helicobacter pylori. The Lancet. 1993;342(8871):575–577.
7. Bittenbring JT, Neumann F, Altmann B, et al. Vitamin D deficiency impairs rituximab-mediated cellular cytotoxicity and outcome of patients with diffuse large B-cell lymphoma treated with but not without rituximab. Journal of Clinical Oncology. 2014;32(29):3242–3248.

This article is for education only. It is not medical advice and does not diagnose or treat any condition. Cancer Expert MD has no financial relationship with any laboratory, drug maker, supplement company, clinic or hospital.